The Market Fieldbook

Confirming your account

Your account is being prepared. You will be redirected securely in a moment.

The Market Fieldbook

Company Observatory

PBH

Prestige Consumer Healthcare Inc.

Healthcare · Medical - Distribution

Overall research band Mixed
Quality Weak
Valuation Exceptional
Balance sheet Very weak
Market confirmation Very weak

One-minute company read

What this report can tell you now

What the company does

Prestige Consumer Healthcare Inc. develops, manufactures, markets, and distributes non-prescription health and personal care products in the U.S. and internationally. The company operates through two main segments: North American Over-the-Counter Healthcare and International Over-the-Counter Healthcare. Its portfolio includes well-known brands such as BC/Goody's (pain relief), Boudreaux's Butt Paste (infant care), Chloraseptic (sore throat), Clear Eyes and TheraTears (vision care), Compound W (wart treatment), DenTek (dental hygiene), Debrox (earwax removal), Dramamine (motion sickness), Fleet and Gaviscon (digestive aids), Luden's (cough suppressant), Monistat and Summer's Eve (feminine hygiene), Nix (lice treatment), Fess (nasal wash), and Hydralyte (rehydration). Prestige Consumer Healthcare sells its products through a variety of retail channels, including discount stores, drugstores, supermarkets, dollar stores, convenience stores, club stores, and e-commerce platforms. The company was founded in 1996 and is headquartered in Tarrytown, New York.

The current research profile is Mixed Setup, with weak market confirmation. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

No single strength should be treated as decisive without reviewing the underlying evidence and data status.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

  • Read the latest filing or company update.
  • Check the financial period behind each metric.
  • Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC8.2%Model input; read with the evidence status and period context.
Operating margin28.4%Model input; read with the evidence status and period context.
Revenue CAGR · 4 years0.0%Model input; read with the evidence status and period context.
FCF margin23.4%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.
Evidence detailSee exact inputs, source context, and model-aware metrics.
HistoryReview score and research changes over time.
MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.